FDA approved Kyprolis (carfilzomib) in combination with lenalidomide and dexamethasone for the treatment of patients with relapsed multiple myeloma who have received one to three prior lines of therapy. Kyprolis is sponsored by Onyx Pharmaceuticals Inc., an Amgen subsidiary.
The United States is projected to lose its measles elimination status, marking a troubling reversal after more than two decades in which the virus was no longer considered endemic.
